Immutrin (private company)
See something wrong or missing? Let us know
Offices:London
Business model:B2B
Immutrin is a British biotech startup developing next‑generation antibody therapies to clear amyloid deposits and reverse amyloidosis.
Investors:
we tracked 6 investors
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
values in USD
Investments 88.33M
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Companies with similar profile to Immutrin
| Name | Criteria | |
|---|---|---|
![]() |
Ability Pharma
70%
|
|
![]() |
AbolerIS Pharma
70%
|
|
![]() |
Acesion Pharma
70%
|
|
![]() |
Beckley Psytech
70%
|
|
![]() |
CatalYm
70%
|
|
![]() |
Citryll
70%
|
|
![]() |
Inbrain Neuroelectronics
70%
|
|
![]() |
InnovaFeed SAS
70%
|
|
![]() |
Memo Therapeutics
70%
|
|
![]() |
NMD Pharma
70%
|
|







Belgium
Austria
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Sweden
Ireland
Italy
Portugal